North Carolina is home to Research Triangle Park, an R&D sanctuary situated between the cities of Raleigh and Durham, which just happens to be one of the biggest biotech hubs in the U.S., with a multitude of renowned companies. The southeastern state even rivals the likes of Boston, San Francisco, Los Angeles, and San Diego, […]
Sensorion, which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, has reported further analysis from its Proof of Concept (POC) phase 2a clinical trial of SENS-401 for residual hearing preservation in adult patients following cochlear implantation. In June 19, Sensorion announced that in preliminary […]
More than 1.5 billion people – nearly 20% of the world’s population – live with hearing loss globally, with 430 million suffering from disabling hearing loss. In this article, we take a look at five of the top hearing loss companies making efforts to reduce these figures. According to the World Health Organization (WHO), nearly […]
The dawn of the 21st century witnessed the success of the Human Genome Project, the quiver of the Braille glove and the ease of obtaining both an ancestry profile and a diagnosis for genetic disorders from a do-it-yourself at-home DNA test kit. Advancements in healthcare since then have been aplenty – with various new therapies […]
At present, more than 1.4 billion people live with hearing loss globally. Hearing disorders are often caused by aging, frequent exposure to loud noises and even hereditary factors. In this article, we will look at some of the latest advancements in hearing disorders research which could broaden the scope for treatments and other measures to […]
Sensorion and EVEON are collaborating on the design and development of an injection system for the delivery of Sensorion’s gene therapy products to the inner ear. Therapies for treating genetic hearing loss are often challenging due to the need for delivery into the inner ear, a very small and delicate organ embedded in the temporal […]
Sensorion has announced that the first patient has been enrolled in its phase 2a proof of concept clinical trial of SENS-401 (Arazasetron) in patients suffering from cisplatin-induced ototoxicity. Cisplatin and other platinum-based compounds are essential chemotherapeutic agents for many cancers. A serious side effect of these therapies is ototoxicity, or permanent and irreversible hearing loss, […]
Sensorion has announced that the US Food and Drug Administration (FDA) has granted rare pediatric disease designation to its lead therapy gene candidate, OTOF-GT. The gene therapy is intended for the treatment of otoferlin gene mediated hearing loss. Sensorion’s OTOF-GT gene therapy development program aims to restore hearing in people living with otoferlin deficiency, one […]
Biotech company, Sensorion, today (October 24) announced that the initiation of a proof of concept (PoC) clinical trial of SENS-401 (Arazasetron) in patients with Cisplatin-Induced Ototoxicity (CIO) has been approved by the regulatory authorities in France. Cisplatin and other platinum-based compounds are essential chemotherapeutic agents for many cancers. A serious side effect of these therapies […]
The European Medicines Agency (EMA) through its Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion for a treatment for otoferlin gene mediated hearing loss. Clinical-stage biotech, Sensorion, announced the news today (September 12) that its application for an Orphan Drug Designation (ODD) for its lead therapy gene candidate, OTOF-GT will now be […]